Abiomed Automated Impella Controller Injury and Death Lawsuit Lawyers

FDA Issues Most Serious Recall Classification After Software Error in Automated Impella Controllers Linked to Reported Injuries and Death

What Parker Waichman LLP Found

• The FDA classified the Abiomed correction as a Class I recall, its most serious recall category.
• An internal software error may cause Automated Impella Controllers to unexpectedly restart.
• During a restart, the heart pump can stop providing circulatory support for up to approximately 75 seconds.
• Federal regulators reported two serious injuries and one death associated with the issue.
• Patients and families affected by complications may have legal rights under product liability laws.

The U.S. Food and Drug Administration has identified an urgent medical device correction involving Abiomed’s Automated Impella Controllers (AICs) as a Class I recall, the agency’s most serious recall classification. A Class I recall is reserved for situations in which continued use of a medical device may cause serious injury or death. Although the affected controllers are not being removed from hospitals or healthcare facilities, the FDA has determined that healthcare providers must immediately follow updated instructions because of a potentially dangerous software defect.

The correction affects Automated Impella Controllers used with left ventricular Impella heart pump systems. These devices play a critical role in supporting patients suffering from severe cardiac conditions, including cardiogenic shock and other situations where the heart cannot adequately pump blood throughout the body. Because patients relying on Impella support are often critically ill, any interruption in device function can have devastating consequences.

According to the FDA and Abiomed, a software issue may cause the Automated Impella Controller to unexpectedly restart under specific circumstances. During the restart process, the heart pump can temporarily stop functioning, leaving vulnerable patients without necessary circulatory support. Federal regulators have reported that this issue has already been associated with serious injuries and a patient death.

For patients and families affected by this medical device issue, the recall raises significant questions about device safety, software reliability, manufacturer responsibilities, and potential legal rights.

Understanding the Role of the Automated Impella Controller

The Automated Impella Controller serves as the primary operating platform for the Impella heart pump system. The controller regulates the pump, monitors performance, displays patient information, and alerts healthcare providers to potential problems.

Impella devices are commonly used in patients whose hearts are unable to pump sufficient blood to support vital organs. The system is designed to reduce strain on the heart while maintaining blood circulation throughout the body. In many cases, the device is used during life-threatening cardiac emergencies when patients require immediate mechanical circulatory support.

Unlike many medical devices that serve a monitoring function only, the Impella system directly contributes to sustaining circulation. This means that any interruption in pump function may quickly affect blood flow to critical organs, including the brain, kidneys, liver, and lungs.

Patients supported by these devices are frequently among the most medically fragile individuals in a hospital setting. Even brief interruptions in circulatory support may increase the risk of organ damage, worsening cardiac function, stroke, or death.

Because the controller is responsible for managing the operation of the Impella catheter, software reliability is not simply a convenience issue. It is a matter of patient survival.

The Software Error That Triggered the Recall Correction

According to information released by the FDA and Abiomed, the problem stems from an internal software error that can force the Automated Impella Controller to restart unexpectedly.

The issue may occur when a patient is receiving support through a left ventricular Impella device and experiences an extended period of reduced pulsatility lasting more than 80 minutes. If a sudden change in left ventricular pressure occurs while the controller is actively calculating left ventricular pressure at support levels above P-3, the software may trigger a controller reboot. This malfunction can occur even if healthcare providers disable certain display features. Abiomed specifically reported that disabling the aortic placement signal or left ventricular pressure display does not prevent the restart from occurring.

When the reboot takes place, the controller screen may suddenly turn black. More importantly, the pump can stop functioning during the restart sequence. During that period, the patient may lose critical hemodynamic support.

The FDA has reported that the interruption may last long enough to create significant medical risks. Preliminary information indicates that the total time required for the pump to stop, restart, and return to its previous support level may take as long as 75 seconds.

For critically ill cardiac patients, more than a minute without adequate circulatory support can represent a medical emergency.

Why Temporary Loss of Impella Support Can Be Dangerous

Mechanical circulatory support devices exist because the heart cannot perform its normal function adequately. Patients dependent upon Impella therapy often have limited ability to tolerate interruptions in blood flow.

During an unexpected controller restart, blood circulation may be compromised. In addition to the loss of support, regulators have warned that regurgitation through the cannula may occur while the pump is not operating.

Potential consequences may include:

• Reduced blood flow to vital organs
• Worsening cardiogenic shock
• Cardiac instability
• Organ injury caused by reduced perfusion
• Stroke
• Neurological injury
• Multi-organ failure
• Death

Patients who lack alternative forms of mechanical support are considered particularly vulnerable. The FDA specifically noted that patients without additional mechanical circulatory support systems may face an increased risk of serious injury or death when a restart occurs.

This concern becomes even more significant because replacement of the controller does not eliminate the risk. Abiomed has acknowledged that exchanging one Automated Impella Controller for another may result in the same software-related restart event.

Reported Injuries and Death Associated With the Defect

Medical device recalls frequently occur before injuries are reported. In this situation, however, federal regulators have already documented serious patient harm.

As of April 27, Abiomed reported:

• Two serious injuries
• One patient death

The existence of reported injuries and a fatality substantially increases concerns surrounding the software issue. When a device intended to preserve life is linked to severe patient outcomes, investigators often examine whether the manufacturer acted appropriately in designing, testing, validating, monitoring, and correcting the product.

Medical device litigation frequently focuses on questions such as:

• Whether the defect could have been identified earlier.
• Whether software testing was adequate.
• Whether warning information was sufficient.
• Whether hospitals received timely notice.
• Whether safer alternative designs existed.
• Whether post-market surveillance detected warning signs.

While each case requires a detailed investigation, reports of injury and death often become a central focus in determining liability.

Why Software Defects Are Increasingly Becoming a Medical Device Safety Issue

Modern medical devices rely heavily on software to perform essential functions. As healthcare technology becomes more sophisticated, software errors can create risks comparable to traditional manufacturing defects.

Unlike a broken component that may be visible during inspection, software defects often remain hidden until specific operating conditions occur. A device may function normally for months or years before a programming error emerges under particular circumstances.

The healthcare industry has seen a growing number of recalls involving software failures in:

• Cardiac devices
• Infusion pumps
• Ventilators
• Imaging systems
• Monitoring equipment
• Surgical robotics

When software controls life-sustaining functions, even a brief malfunction can have catastrophic consequences. Manufacturers are expected to implement rigorous software validation, testing, quality assurance, and post-market monitoring procedures. Failure to identify or correct software defects can expose patients to preventable harm.

Potential Legal Claims Involving Defective Medical Devices

Patients injured by defective medical devices may have legal rights under product liability laws. Depending on the facts of a particular case, claims may involve allegations that a device contained design defects, software defects, inadequate warnings, manufacturing defects, or negligent safety practices.

Medical device lawsuits often focus on whether the product performed as intended and whether known risks were properly disclosed.

Compensation may be available for:

• Medical expenses
• Additional surgeries or procedures
• Hospitalization costs
• Rehabilitation expenses
• Lost income
• Pain and suffering
• Permanent disability
• Wrongful death damages

Cases involving life-sustaining cardiac devices frequently require extensive review of medical records, device performance data, engineering evidence, adverse event reports, and regulatory findings. Because each patient’s medical condition is unique, determining causation often requires careful analysis by qualified medical and engineering professionals.

What Patients and Families Should Know Moving Forward

Abiomed has stated that hospitals may continue using affected controllers while following updated instructions. The company is reportedly developing a software update intended to address the issue.

Patients currently receiving treatment should not discontinue medical care or make changes to treatment plans without consulting their healthcare providers. However, patients and families may wish to discuss whether an affected controller was involved in their care and whether any device-related complications occurred.

Medical records, device logs, hospital incident reports, and FDA adverse event information may become important evidence when investigating potential claims involving device malfunctions.

As additional information becomes available regarding the reported injuries, death, and corrective actions, further scrutiny of the device’s performance may occur.

Impella Controller Malfunction Lawsuit FAQs

Can patients file a lawsuit if an Impella controller malfunction contributed to an injury?

Potentially, yes. If evidence shows that a software defect, device failure, or inadequate warning contributed to a patient’s injury, legal claims may be available. Each case requires a detailed review of medical records, device information, and the circumstances surrounding the event.

Does a recall automatically mean there is a valid lawsuit?

No. A recall alone does not establish liability. However, a recall can serve as important evidence when evaluating whether a device was defective and whether that defect contributed to a patient’s injuries. Every case depends on the specific facts and medical evidence involved.

Can families pursue a wrongful death claim if a loved one died after a device malfunction?

In some situations, surviving family members may have the right to pursue a wrongful death claim. Such claims generally focus on whether a defective product contributed to the death and whether the manufacturer or other parties may be legally responsible.

What evidence is important in a medical device lawsuit?

Evidence may include medical records, device logs, hospital reports, FDA documents, recall notices, physician notes, adverse event reports, and expert analysis. Preserving records as early as possible can be important when investigating potential claims.

What compensation may be available in a defective medical device case?

Potential damages can include medical expenses, future treatment costs, lost earnings, pain and suffering, disability-related losses, and wrongful death damages. The amount depends on the nature and severity of the injuries and the evidence supporting the claim.

Contact Parker Waichman LLP For A Free Case Review

Patients receiving mechanical circulatory support depend on medical devices to function properly when their lives are on the line. When a software defect or device malfunction allegedly contributes to serious injury or death, families deserve answers and accountability.

If you or a loved one suffered complications, injury, or loss that may be connected to an Abiomed Automated Impella Controller malfunction, Parker Waichman LLP is investigating potential claims involving this medical device issue.

Parker Waichman LLP represents injured patients and families nationwide in product liability and medical device litigation. The firm offers free consultations and can review the circumstances surrounding your potential claim.

Call 1-800-YOUR-LAWYER (1-800-968-7529) today for a free case evaluation. Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.